StockData
LENSAR, Inc. logo

LENSAR, Inc. (LNSR) stock

LNSRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3022% below fair value
$4.85−0.06 (-1.22%)

Close on Nov 18, 2026Market cap $59.59MP/E –Yield –

Lensar r&d expenses

Research and development expenses are spending on new products and technology.

Lensar's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.32M, down 3.2% year over year. For fiscal 2025 it was $5.62M, up 5.5% from the year before. The highest annual figure on record is $12.36M in fiscal 2021.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$5.62M+5.5%
FY2024Dec 31, 2024$5.33M-13.2%
FY2023Dec 31, 2023$6.14M-48.0%
FY2022Dec 31, 2022$11.81M-4.4%
FY2021Dec 31, 2021$12.36M+63.6%
FY2020Dec 31, 2020$7.55M-0.2%
FY2019Dec 31, 2019$7.57M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.27M-10.7%
Q1 FY2026Mar 31, 2026$1.39M-9.7%
Q4 FY2025Dec 31, 2025$1.30M-2.9%
Q3 FY2025Sep 30, 2025$1.37M+13.7%
Q2 FY2025Jun 30, 2025$1.43M+5.7%
Q1 FY2025Mar 31, 2025$1.53M+6.2%
Q4 FY2024Dec 31, 2024$1.34M-8.7%
Q3 FY2024Sep 30, 2024$1.20M-21.3%
Q2 FY2024Jun 30, 2024$1.35M-10.1%
Q1 FY2024Mar 31, 2024$1.44M-12.5%
Q4 FY2023Dec 31, 2023$1.46M-9.4%
Q3 FY2023Sep 30, 2023$1.53M-3.2%
Q2 FY2023Jun 30, 2023$1.50M-60.9%
Q1 FY2023Mar 31, 2023$1.65M-65.5%
Q4 FY2022Dec 31, 2022$1.62M-52.8%
Q3 FY2022Sep 30, 2022$1.58M-50.5%
Q2 FY2022Jun 30, 2022$3.83M+27.5%
Q1 FY2022Mar 31, 2022$4.79M+74.4%
Q4 FY2021Dec 31, 2021$3.42M+34.6%
Q3 FY2021Sep 30, 2021$3.18M+58.8%
Q2 FY2021Jun 30, 2021$3.01M+109.6%
Q1 FY2021Mar 31, 2021$2.75M+74.8%
Q4 FY2020Dec 31, 2020$2.54M+80.4%
Q3 FY2020Sep 30, 2020$2.01M-53.7%
Q2 FY2020Jun 30, 2020$1.43M–
Q1 FY2020Mar 31, 2020$1.57M–
Q4 FY2019Dec 31, 2019$1.41M–
Q3 FY2019Sep 30, 2019$4.33M–

More Lensar figures

See a number that looks wrong?